Aquestive Therapeutics, Inc. (NASDAQ:AQST) Short Interest Update

Aquestive Therapeutics, Inc. (NASDAQ:AQST – Get Rating) saw a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 2,030,000 shares, a growth of 5.7% from the February 13th total of 1,920,000 shares. Based on an average daily volume of 276,400 shares, the days-to-cover ratio is currently 7.3 days.

Analyst Ratings Changes

Separately, Wedbush raised Aquestive Therapeutics from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $3.00 to $4.00 in a research report on Thursday, March 9th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $8.30.

Aquestive Therapeutics Trading Up 2.6 %

NASDAQ AQST opened at $0.78 on Friday. The firm has a market capitalization of $42.13 million, a P/E ratio of -0.68 and a beta of 2.69. The business has a fifty day simple moving average of $0.86 and a 200 day simple moving average of $0.96. Aquestive Therapeutics has a 12 month low of $0.62 and a 12 month high of $2.94.

Aquestive Therapeutics (NASDAQ:AQST – Get Rating) last announced its quarterly earnings data on Wednesday, March 8th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.02). The business had revenue of $10.68 million during the quarter, compared to analysts’ expectations of $9.93 million. During the same period in the previous year, the business earned ($0.38) EPS. As a group, sell-side analysts predict that Aquestive Therapeutics will post -0.78 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC grew its stake in shares of Aquestive Therapeutics by 204.7% during the 1st quarter. Renaissance Technologies LLC now owns 34,300 shares of the company’s stock worth $90,000 after acquiring an additional 23,043 shares during the period. BNP Paribas Arbitrage SA grew its stake in shares of Aquestive Therapeutics by 118.2% during the 1st quarter. BNP Paribas Arbitrage SA now owns 34,810 shares of the company’s stock worth $91,000 after acquiring an additional 18,860 shares during the period. Beacon Pointe Advisors LLC bought a new position in Aquestive Therapeutics in the 2nd quarter worth about $38,000. Mackenzie Financial Corp bought a new position in Aquestive Therapeutics in the 2nd quarter worth about $39,000. Finally, State Street Corp boosted its stake in Aquestive Therapeutics by 10.3% in the 1st quarter. State Street Corp now owns 96,037 shares of the company’s stock worth $251,000 after purchasing an additional 8,960 shares during the period. Institutional investors own 29.35% of the company’s stock.

About Aquestive Therapeutics

(Get Rating)

Aquestive Therapeutics, Inc engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.